Clinical trials: Adenocarcinoma of the Prostate
Prostate Cancer
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as ketoconazole, may stop the adrenal glands from making androgens.
- Trial name
- NCT00460031
- Testing
- ketoconazole, lenalidomide, therapeutic hydrocortisone
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as sirolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00311623
- Testing
- Rapamycin 3mg, Rapamycin 6mg, Radical prostatectomy
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Adenocarcinoma
Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy
This trial studies how well increasing the dose of survivorship care planning improves care and outcomes in prostate cancer survivors receiving radiation therapy and androgen deprivation therapy.
- Trial name
- NCT03860961
- Testing
- Survivorship Care Plan, Treatment Plan
- Where
- 79 sites in United States
- Volunteers
- 550 people
- Sponsor
- NRG Oncology
Prostate Cancer
Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy
The main objective of this multicenter, randomized, double-blind, placebo-controlled phase III trial is to assess the impact of maintenance orteronel on disease progression and hence on quality of life in patients with metastatic…
- Trial name
- NCT01707966
- Testing
- Orteronel
- Where
- 15 sites in Switzerland
- Volunteers
- 47 people
- Sponsor
- Swiss Cancer Institute
Prostate Cancer
Pomegranate Juice in Treating Patients With Recurrent Prostate Cancer
RATIONALE: Pomegranate juice may contain substances that decrease or slow the rise of prostate-specific antigen (PSA) levels and may be effective in delaying or preventing recurrent prostate cancer.
- Trial name
- NCT00060086
- Testing
- pomegranate juice
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adenocarcinoma of Prostate
Short Course Radiotherapy for Localized Prostate Cancer
Hypofractionated external beam radiotherapy has been clinically used for localized prostate cancer in view of the low estimated alpha/beta ratio of prostate cancer cells.
- Trial name
- SHORT (NCT03518853)
- Testing
- Short-course Hypofractionated Once-weekly Radiation Therapy
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Tata Medical Center
Prostate Cancer
Observation of Outcomes and Side Effects of Cesium-131 in Combination With External Beam Radiation for the Treatment of Intermediate to High Risk Prostate Cancer
The purpose of this study is to observe PSA response and incidence of side effects in patients diagnosed with intermediate to high risk prostate cancer and treated with Cesium-131 in combination of external beam therapy.
- Trial name
- NCT00621413
- Where
- 9 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- IsoRay Medical, Inc.
Prostate Cancer
Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00045227
- Testing
- recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
This study is a Phase 1/2 open-label involving 2 groups of patients newly diagnosed with either unfavorable intermediate risk or high risk prostate adenocarcinoma.
- Trial name
- NCT02805894
- Testing
- NBTXR3 activated by IMRT only, NBTXR3 activated by Brachytherapy & IMRT
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Nanobiotix
Prostate Cancer
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00567580
- Testing
- PBRT, PLNRT, AA
- Where
- 460 sites in United States, Canada and 2 more
- Volunteers
- 1,792 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Adenocarcinoma, Prostate Cancer
PSMA PET Imaging of Recurrent Prostate Cancer
The purpose of this study is to see if a new diagnostic research agent named 68Ga-HBED-CC-PSMA can show prostate cancer on a PET/CT scan that cannot be seen on other standard imaging even when the PSA levels are very low.
- Trial name
- NCT03204123
- Testing
- Ga-HBED-iPSMA PET, PET/CT, MRI
- Where
- 7 sites in United States
- Volunteers
- 1,171 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide and bicalutamide, may lessen the amount of androgens made by the body.
- Trial name
- NCT00684905
- Testing
- bicalutamide, leuprolide acetate, adjuvant therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Prostate Adenocarcinoma
Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
This phase II trial studies how well apalutamide works in treating patients with prostate cancer who are in active surveillance. Testosterone can cause the growth of prostate cancer cells.
- Trial name
- NCT02721979
- Testing
- Apalutamide, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Washington
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced…
- Conditions
- Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT07006727
- Testing
- 225Ac-ETN029, 111In-ETN029
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Adenocarcinoma of the Prostate
Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
Open-label, dose rising, Phase IIa trial of intratumorally-injected NanoPac® 6, 10, or 15 mg/mL in subjects with prostate cancer scheduled for prostatectomy.
- Trial name
- NCT03077659
- Testing
- NanoPac®
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- NanOlogy, LLC
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
This phase II trial tests whether 177-Lutetium-PSMA given before stereotactic body radiotherapy (SBRT) works to improve cancer control rate in patients with 1-5 prostate cancer tumors that have come back after prior treatment…
- Conditions
- Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- LUNAR (NCT05496959)
- Testing
- Lutetium Lu-177 PNT2002, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Blood Pressure, Hypertension
Onco-primary Care Networking to Support TEAM-based Care
The proposed ONE TEAM Study is an 18-month, cluster randomized controlled trial. This study will use a sequential multiple assignment randomized trial (SMART) design with a second randomization for the intervention group using a…
- Conditions
- Blood Pressure, Hypertension, Cancer, Cancer, Breast
- Trial name
- ONE TEAM (NCT04258813)
- Testing
- iGuide Intervention (Self-guided), iGuide 2 Intervention (Tailored/Targeted), Control
- Where
- United States
- Volunteers
- 313 people
- Sponsor
- Duke University
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT04423211
- Testing
- 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography
- Where
- 341 sites in United States
- Volunteers
- 804 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Prostate Cancer
Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using exemestane plus bicalutamide may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00031889
- Testing
- Exemestane, Exemestane+bicalutamide
- Where
- 12 sites in Switzerland
- Volunteers
- 5 people
- Sponsor
- Swiss Cancer Institute
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well orteronel works in treating patients with metastatic hormone-resistant prostate cancer. Orteronel may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01866423
- Testing
- orteronel, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Southern California